Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Anemia, Refractory, with Excess of Blasts 2Neoplasms, Plasma Cell 1Lymphoma, Mantle-Cell 1Hemoglobinuria, Paroxysmal 1Anemia, Aplastic 1

Interventions

Melphalan 5fludarabine phosphate 4Whole-Body Irradiation 4Peripheral Blood Stem Cell Transplantation 3Busulfan 3Tacrolimus 2Mycophenolic Acid 2Methotrexate 2Cyclophosphamide 2Alemtuzumab 2thymoglobulin 1merphos 1Transplantation, Homologous 1Sirolimus 1Etoposide 1Cyclosporine 1Basiliximab 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hemoglobinuria, Paroxysmal × Basiliximab × Plasma cell × Clear all
NCT00975975 2016-02-26

Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer

Indiana University

Phase 2 Completed
17 enrolled 9 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Anemia, Refractory, with Excess of Blasts, Hemoglobinuria, Paroxysmal, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡